May 16, 2011

Mount Sinai School of Medicine and Pacific Biosciences Partner to Advance Clinical Research through Institute for Genomics and Multiscale Biology

Institute to be Directed by PacBio CSO Dr. Eric Schadt; Will

Include Single Molecule Real Time Biology User Facility


Mount Sinai School of Medicine (Mount Sinai) and Pacific Biosciences of

California, Inc. (NASDAQ: PACB) announced a bi-coastal collaboration to

advance clinical research through the Mount Sinai Institute for Genomics

and Multiscale Biology to be led by Eric E. Schadt, Ph.D. The Institute

is the hub of genomics research at Mount Sinai, collaborating with 13

other disease oriented and core technology based Institutes at Mount

Sinai. One of the world’s foremost experts in computational biology, Dr.

Schadt will direct the Institute, and also continue in his role as Chief

Scientific Officer of Pacific Biosciences.

As part of the collaboration, a Single Molecule Real Time (SMRT™)

Biology User Facility will be established within the Institute.

Developed by Pacific Biosciences, SMRT technology allows for the

real-time analysis of biomolecules with single molecule resolution,

providing a window into biological processes that has not previously

been open for study.

“The large-scale generation and integration of multiple sources of

biological data combined with clinical information will expand our

ability to characterize disease, and ultimately help develop and improve

the diagnosis and treatment of patients. This is the primary research

mission of Mount Sinai School of Medicine,” said Dennis S. Charney,

M.D., Dean of Mount Sinai School of Medicine. “With unprecedented access

to Pacific Biosciences’ revolutionary technology and under the direction

of Dr. Schadt, the Institute for Genomics and Multiscale Biology will be

at the forefront of the revolution in genetics and genomic sciences,

which will fundamentally change the practice of medicine.”

Dr. Schadt is an expert on the generation and integration of very

large-scale sequence variation, molecular profiling and clinical data in

disease populations for constructing molecular networks that define

disease states and link molecular biology to physiology. His research

has provided novel insights into what is needed to master diverse,

large-scale data collected on normal and disease populations in order to

elucidate the complexity of disease and make more informed decisions in

the drug discovery arena. He has contributed to a number of discoveries

relating to the genetic basis of common human diseases such as diabetes

and obesity, which have been widely published in leading scientific


“The alliance between PacBio and Mount Sinai, and my dual role working

with both organizations, will allow us to bring together the components

required to catapult a new paradigm for clinical research and

translational medicine,” said Dr. Schadt. “Multiscale data integration,

including genomic, expression, metabolite, protein, and clinical

information, will ultimately define the future of patient care. With our

intent to collaborate in areas such as newborn screening for rare

genetic disorders, infectious diseases and cancer we hope to accelerate

this revolution, starting by integrating clinical data with previously

untapped biological information to build new computational models for

predicting human disease.”

Dr. Schadt is also a founding member of Sage Bionetworks, an open access

genomics initiative designed to build and support databases and an

accessible platform for creating innovative dynamic disease

models. Prior to joining Pacific Biosciences in 2009, he was Executive

Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of

Merck & Co., Inc. in Seattle. Prior to joining Rosetta, Dr. Schadt was a

Senior Research Scientist at Roche Bioscience. He received his B.A. in

applied mathematics and computer science from California Polytechnic

State University, his M.A. in pure mathematics from University of

California, Los Angeles (UCLA), and his Ph.D. in bio-mathematics from


The SMRT Biology User Facility at Mount Sinai will be equipped with

research and development versions of the PacBio SMRT technology

platforms. These systems, called Astros, have been used by Pacific

Biosciences and its collaborators to examine a number of important

biological processes including DNA sequencing, direct RNA sequencing,

protein translation and ligand binding. The SMRT systems will be

available for use by the Mount Sinai Institute for Genomics and

Multiscale Biology and other collaborators located in the eastern half

of the United States. Pacific Biosciences will also continue to engage

in SMRT biology research collaborations from its headquarters in


“With a strong commitment, shared vision, and extensive access to

patient samples, we believe Mount Sinai is a perfect partner to help

realize the promise of SMRT technology in clinical applications,” said

Hugh Martin, Chairman and Chief Executive Officer of Pacific Biosciences.

For more information about Mount Sinai School of Medicine and the

Institute for Genomics and Multiscale Biology, please visit

For more information about Pacific Biosciences, please visit

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital

and Mount Sinai School of Medicine. Established in 1968, Mount Sinai

School of Medicine is one of few medical schools embedded in a hospital

in the United States. It has more than 3,400 faculty in 32 departments

and 15 institutes, and ranks among the top 20 medical schools both in

National Institute of Health funding and by U.S. News & World Report.

The school received the 2009 Spencer Foreman Award for Outstanding

Community Service from the Association of American Medical Colleges.

About Pacific Biosciences

Pacific Biosciences’ mission is to transform the way humankind acquires,

processes and interprets data from living systems through the design,

development and commercialization of innovative tools for biological

research. The company has developed a novel approach to studying the

synthesis and regulation of DNA, RNA and proteins. Combining recent

advances in nanofabrication, biochemistry, molecular biology, surface

chemistry and optics, Pacific Biosciences has created a powerful

technology platform called single molecule, real-time, or SMRT™,

technology. SMRT technology enables real-time analysis of biomolecules

with single molecule resolution, which has the potential to transform

the understanding of biological systems by providing a window into these

systems that has not previously been open for scientific study.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking

statements may contain words such as “believe,” “may,” “estimate,”

“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of

these terms, or other similar expressions, and include the assumptions

that underlie such statements. Such statements include, but are not

limited to, statements regarding the Company’s SMRT technology. These

statements are subject to known and unknown risks and uncertainties that

could cause actual results to differ materially from those expressed or

implied by such statements, including but not limited to risks discussed

from time to time in documents Pacific Biosciences of California, Inc.

has filed with the Securities and Exchange Commission, including the

risks identified under the section captioned “Risk Factors” in its

recently filed Quarterly Report on Form 10-Q. All forward-looking

statements are based on estimates, projections and assumptions as of the

date hereof. Pacific Biosciences undertakes no obligation to update any

forward-looking statements.

Photos/Multimedia Gallery Available:

For Mount Sinai School of Medicine:
The Mount Sinai Medical

CenterIan Michaels, 212-241-9200

Pacific Biosciences:

Pacific BiosciencesNicole Litchfield, 415-793-6468

BiosciencesTrevin Rard, 650-521-8450

Source: Pacific Biosciences

News Provided by Acquire Media

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.